VEGFA and neoplasm: Thus, novel therapy concepts targeting sVEGFR2 and other VEGF group members to normalize vascularization in therapy-resistant tumor tissue should be developed together with biomarkers, such as serum or protein expression levels during anticancer treatment [47].